Sorbent's lead heart failure product shows Phase II promise
This article was originally published in Scrip
Executive Summary
The private US biopharmaceutical company Sorbent Therapeutics has presented promising Phase II data for its lead drug candidate, CLP1001, at a late-breaking clinical trials session at the ESC Heart Failure Congress in Belgrade, Serbia.